Data from MicroRNA <i>MIR21</i> and T Cells in Colorectal Cancer
Kosuke Mima,Reiko Nishihara,Jonathan A. Nowak,Sun A. Kim,Mingyang Song,Kentaro Inamura,Yasutaka Sukawa,Atsuhiro Masuda,Juhong Yang,Ruoxu Dou,Katsuhiko Nosho,Hideo Baba,Edward L. Giovannucci,Michaela Bowden,Massimo Loda,Marios Giannakis,Adam J. Bass,Glenn Dranoff,Gordon J. Freeman,Andrew T. Chan,Charles S. Fuchs,Zhi Rong Qian,Shuji Ogino
DOI: https://doi.org/10.1158/2326-6066.c.6548744
2023-01-01
Abstract:<div>Abstract<p>The complex interactions between colorectal neoplasia and immune cells in the tumor microenvironment remain to be elucidated. Experimental evidence suggests that microRNA <i>MIR21</i> (miR-21) suppresses antitumor T-cell–mediated immunity. Thus, we hypothesized that tumor <i>MIR21</i> expression might be inversely associated with T-cell density in colorectal carcinoma tissue. Using 538 rectal and colon cancer cases from the Nurses' Health Study and the Health Professionals Follow-up Study, we measured tumor <i>MIR21</i> expression by a quantitative reverse-transcription PCR assay. Densities of CD3<sup>+</sup>, CD8<sup>+</sup>, CD45RO (PTPRC)<sup>+</sup>, and FOXP3<sup>+</sup> cells in tumor tissue were determined by tissue microarray immunohistochemistry and computer-assisted image analysis. Ordinal logistic regression analysis was conducted to assess the association of <i>MIR21</i> expression (ordinal quartiles as a predictor variable) with T-cell density (ordinal quartiles as an outcome variable), adjusting for tumor molecular features, including microsatellite instability; CpG island methylator phenotype; <i>KRAS</i>, <i>BRAF</i>, and <i>PIK3CA</i> mutations; and LINE-1 methylation. We adjusted the two-sided α level to 0.012 for multiple hypothesis testing. Tumor <i>MIR21</i> expression was inversely associated with densities of CD3<sup>+</sup> and CD45RO<sup>+</sup> cells (<i>P</i><sub>trend</sub> < 0.0005). The multivariate odds ratio of the highest versus lowest quartile of <i>MIR21</i> for a unit increase in quartile categories of CD3<sup>+</sup> or CD45RO<sup>+</sup> cells was 0.44 [95% confidence interval (CI), 0.28 to 0.68] or 0.41 (95% CI, 0.26–0.64), respectively. Our data support a possible role of tumor epigenetic deregulation by noncoding RNA in suppressing the antitumor T-cell–mediated adaptive immune response and suggest <i>MIR21</i> as a potential target for immunotherapy and prevention in colorectal cancer. <i>Cancer Immunol Res; 4(1); 33–40. ©2015 AACR</i>.</p></div>